TRACON Pharmaceuticals, Inc. (TCON)

Market Cap	1.61M
Revenue (ttm)	12.15M
Net Income (ttm)	1.75M
Shares Out	2.68M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,401
Open	0.615
Previous Close	0.660
Day's Range	0.601 - 0.615
52-Week Range	0.600 - 14.746
Beta	1.28
Analysts	Hold
Price Target	60.00 (+9,883.36%)
Earnings Date	Aug 12, 2024

About TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 30, 2015
• Employees: 17
• Stock Exchange: OTCMKTS
• Ticker Symbol: TCON

Analyst Forecast

According to 3 analysts, the average rating for TCON stock is "Hold." The 12-month stock price forecast is $60.0, which is an increase of 9,883.36% from the latest price.

Price Target

$60.0

(9,883.36% upside)

Analyst Consensus: Hold